<DOC>
	<DOCNO>NCT02194946</DOCNO>
	<brief_summary>Stage 5 chronic kidney disease ( CKD ) , also end stage renal disease ( ESRD ) , usually present overt clinical symptom critical stage patient encountered dialysis . The optimal time initiate dialysis patient stage 5 CKD address important dialysis-related question . As indicated recently publish European Renal Best Practice ( ERBP ) guideline , early initiation seem produce benefit great expenditure sometimes harm.Renal replacement therapy ( RRT ) include dialysis common procedure patient end-stage renal disease ( ESRD ) , conservative management option patient still experience stable period without clinical indication dialysis.Chinese Medicine ( CM ) recognize alternative therapy alleviate uremic symptom , defer dialysis initiation , improve quality life . Although effect CM kidney disease demonstrate animal experiment , evidence large clinical trial insufficient . So raise hypothesis CM therapies include Chinese herbal formula , Chinese patent medicine via oral pattern and/or Colonic administration , defer initiation dialysis adult stage 5 CKD .</brief_summary>
	<brief_title>Chinese Medicine Deferring Dialysis Initiation</brief_title>
	<detailed_description>Chinese Medicine ( CM ) treatment apply CKD patient commonly China , especially independent dialysis . Based personal experience expert different area China , patient stage 5 CKD treat different formulation herbs include Astragalus membranaceus ( Huangqi ) , Codonopsis pilosula ( Dangshen ) , Semen Cuscutae ( Tusizi ) Radix et Rhizoma Rhei ( Dahuang ) etc . . Based Traditional Chinese Medicine theory clinical practise , herbal medicine help strengthen `` spleen-kidney '' dispel `` turbidity '' . To determine whether CM therapy include Chinese herbal formula , Chinese patent medicine via oral pattern and/or Colonic administration , significantly defer dialysis initiation , conduct Chinese Medicine Deferring Dialysis Initiation ( C-MODDI ) study . It 's multicenter , prospective , controlled trial , also effectiveness study conduct `` real world '' variety busy clinical practice , heterogeneous intervention representative general effectiveness CM therapy .</detailed_description>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Aged 1875 year ; estimate glomerular filtration rate ( eGFR ) 5.515 ml/min per 1.73 m2 ; Nondiabetic CKD , identify biopsy patient ' medical history . East Asian . Clinical indication dialysis still occur conservative kidney management 1 week , rule hemoglobin &lt; 70g/L ; serum potassium &gt; 6.5mmol/L ; Carbon Dioxide Combining Power ( CO2CP ) &lt; 13mmol/L ; EPIGFRâ‰¤5ml/min/1.73m2 ; Pregnant lactating . Critical status , alimentary tract hemorrhage decompensated cirrhosis ; History malignancy successfully completely treated carcinoma ; Any condition ( mental physical ) would interfere patient 's ability comply study protocol ; Concurrent current treatment glucocorticoid immunosuppressant agent last 3 month ; Participation clinical trial ; Known suspect allergy certain agent involve ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Kidney Disease ,</keyword>
	<keyword>End-Stage Renal Disease ,</keyword>
	<keyword>Traditional Chinese Medicine ,</keyword>
	<keyword>dialysis initiation .</keyword>
</DOC>